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Dementia friendly dentistry for the periodontal patient Part 1: 
Recognising and assessing patients with dementia 
Tanya L. Cerajewska and Nicola X. West 
Abstract  
This is the first of two articles that provide a guide for the clinical management of those with dementia who 
present with periodontal disease in dental practice. Conditions that cause dementia and their increasing 
prevalence are described. Advice is given to aid the dental team in recognising patients with dementia. The 
impact that dementia and the medications used in its medical management have on the oral environment 
are also covered.  The complexities of completing an accurate periodontal assessment for those with 
dementia are discussed and indications for best practice provided. Although both articles (Part 1 and Part 
2) centre on periodontal care, much of the content is equally applicable to wider general dental care for 
the dementia patient.  
Key points 
• Summarises the causes and prevalence of dementia. 
• Provides information to aid the recognition of dementia in dental practice. 
• Provides information about the medications used in the management of dementia and their 
relevance to periodontal care. 
• Gives communication strategies to engender patient and carer co-operation with periodontal care. 
Introduction 
Dementia is the term used to describe a group of conditions that gradually destroy cognitive ability, and 
with it the ability to function independently and interact socially.  Many reversible and irreversible 
conditions cause dementia1-3 (Tables 1 & 2). Alzheimer’s disease (AD) accounts for 50-75% of all dementia 
cases, with vascular dementia and dementia with Lewy bodies accounting for a further 20% and 10-15% of 
cases respectively. Frontotemporal dementia accounts for less than 5% of all cases4.  Most forms of 
dementia are life-limiting, incurable, and impact negatively on the individuals affected, their carers and 
loved ones. 
There are currently over 850,000 people in the UK living with dementia, by 2051 this figure is set to rise to 
over 2 million5.  The chance of developing dementia rises exponentially beyond the age of 65 years; 
affecting 1.7% of 65 to 69 year olds and 40% of those over 94 years old6.  There is also a greater prevalence 
of moderate and severe periodontitis among elderly populations7. It has long been speculated that those 
with dementia have increased prevalence of periodontitis due in part to impaired self-care abilities. Current 
evidence supports the co-existence of dementia and periodontitis5 8 9.  Periodontitis has been found to 
have a detrimental impact on AD patients’ quality of life10.  A systematic review of oral hygiene and health 
of older adults with dementia has similarly found that plaque levels were consistently higher for those with 
dementia compared to those without9. The importance of providing periodontal treatment for those with 
AD has been emphasised by studies that indicate a potential connection between worsening oral health 
and AD progression11. In a small, well conducted study, the presence of periodontitis has been associated 
with more rapid rates of cognitive decline in those with AD, compared to those without periodontitis12. 
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The potential role of periodontitis in the pathogenesis of Alzheimer’s disease has been discussed in detail13 
14-17 yet the role and extent to which periodontitis affects the causation and deterioration of Alzheimer’s 
disease remains uncertain. The potential bidirectional pathogenicity between periodontitis and 
Alzheimer’s disease is likely to negatively impact upon the likelihood of reaching periodontal stability. 
Furthermore, the adverse effect that cognitive decline has on oral hygiene is unquestionable and a limiting 
factor in reaching periodontal stability. 
Despite the apparent need for quality periodontal care for those with dementia, numerous authors have 
found that people with dementia are less likely to seek dental care9,18,2. A cohort study of 158 patients with 
varying severities of AD, found 87% had periodontal probing depths of 4mm and greater, there was plaque 
at an average of 71% of tooth surfaces, and rather alarmingly nearly 40% of periodontally involved teeth 
had grade 3 tooth mobility10. Addressing the unmet periodontal and dental treatment needs of people 
with dementia will require a combined approach between dental teams, carers, care co-ordinators, 
medical teams and clinical networks to improve the provision of dental services for those with dementia.  
People with dementia can present in challenging and unusual ways to the dental team. Regardless of our 
patients’ circumstances, cognitive abilities or demeanour, as clinicians it is our duty to provide functional 
dentistry to all, without bias or prejudice.  There are several components that need to be appreciated to 
enable quality dental and periodontal care for those affected by dementia, these are represented in Figure 
1, and discussed in more detail in the following sections. Barriers to the provision of quality dentistry for 
the dementia patient are often associated with limitations on available clinical time and a lack of 
understanding of the best way to manage those who have dementia in the dental environment.  This article 
aims to provide a guide to aid understanding and management of those with dementia who present with 
periodontitis in dental practice.  
 
Recognising dementia in dental practice 
One-third of those affected by dementia live in care homes, of the 538,000 affected individuals who do 
not, many of them will receive dental care in general dental practice. Being resident in a care home does 
not exclude patients from general dental practice, however the logistical support that is required means 
that this is only practical for a proportion of patients in care homes.  Over 50% of those living with dementia 
in the UK remain undiagnosed19. As many people are living with undiagnosed dementia, members of the 
dental team may be among the first health care professionals to notice symptoms, particularly where they 
have been involved in the patients care for several years preceding their cognitive decline.  Early 
recognition of dementia is critical to enable suitable dental planning, to reduce the likelihood of future 
morbidity and minimise the risk of crisis management as the severity of dementia increases. 
Common signs and symptoms of dementia are listed in Table 3, each of these must be considered relative 
to the patient’s previous level of ability.  It is therefore useful to know the patient’s previous educational 
attainment, occupation, and drug use, as these factors also impact on cognitive abilities.  Elderly patients 
who become uncharacteristically aggressive, abrupt or irritated may be suffering from early dementia. 
Although dementia can occur suddenly following a traumatic head injury or stroke, in most cases it has a 
gradual onset.  In general, there is memory loss and symptoms from at least one other cognitive domain 
which are severe enough to impact on activities of daily living20.   
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When taking a medical history, it is worth asking all patients: ‘Did a direct blood relative suffer from 
dementia before the age of 65 years?’.  This is because 5% of those who have dementia in the UK developed 
symptoms before their 65th birthday6, this is commonly due to familial forms of AD, inferring a strong risk 
that the patient will also develop dementia relatively early in life. 
As dementia affects more than 7% of people over the age of 65 years6 when taking elderly patient’s medical 
history, it is worth asking: 
• ‘Is your memory as good as it used to be?’  
• ‘Have you ever been diagnosed with memory loss?’  If yes, ‘Did you recover from this?’ 
• ‘Do you need extra help at home?’ If so, ‘What type?’  and ‘How often?’ 
Taking a medical history from someone with moderate dementia is fraught with difficulties, as they may 
not remember they have dementia, other medical conditions or take medications. Patients without 
dementia may not be able to recall the name of a medication but dementia patients may have completely 
forgotten they take a drug or have had a medical consultation.  Even medical histories taken from those 
with mild dementia may have considerable omissions. It is possible, yet unlikely, that a patient who is not 
already known to the practice would present alone as a new patient beyond the early symptoms of 
dementia. If dementia is suspected, yet not elicited from the medical history, before proceeding with 
treatment it is advisable to contact the patient’s GP (given the patient’s consent to do so) to clarify whether 
there is anything in the patients’ medical history that could have dental implications.   
Dentists who are familiar with dementia symptoms and basic screening tools are in the prime position to 
screen for possible dementia.  Whilst dentists do not diagnose dementia, they are able to refer patients to 
medical colleagues if they believe cognitive impairment is likely. This proactive approach will also aid 
appropriate dental treatment planning and care delivery. Following appropriate consent, it is wise to 
communicate with the patient’s GP to relay the information gathered and any concerns you or the patient 
have in relation to their cognitive function.  Requesting information regarding the patient’s dementia 
diagnosis, stage, prognosis and drug regimen is also worthwhile.   
There are a variety of relatively short tests formulated to screen for cognitive impairment in primary care 
settings which have similar accuracy21.  Those most used screen for dementia and classify its severity in a 
valid, reliable and rapid manner. Test Your Memory (TYM)22 is one such test which is suitable for use in 
general practice settings. The questionnaire can be downloaded23 and completed in around 10 minutes.  
10 cognitive tasks are combined on one sheet of paper, answers can be scored rapidly on a 0-50 scale. 
Scores of 30 or less indicate that dementia is likely. With a sensitivity of 73% and specificity of 88%, the 
TYM test is better at detecting true negatives than true positives22. Although screening for possible 
dementia is not a requirement, GDPs who have a particular interest in this area, may find the TYM test is 
an achievable option.  On completion of the test it is important to feedback the findings to the patient, and 
for those who score 30 or less, a medical assessment to explore their memory and thought processes is 
advisable.  
A clinical diagnosis of dementia is made by a medical practitioner, normally following consideration of the 
history taken from the patient and a carer, friend or relative, and performance in cognitive tests over time.  
A diagnosis of AD, the most common cause of dementia, is made by the exclusion of other conditions that 
can be responsible for causing dementia (Tables 1 & 2). Differentiation between the various subtypes of 
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dementia is possible using a neurologic & psychiatric assessment, suitable blood tests (to exclude causes 
such as vitamin deficiencies and hypothyroidism), and structural imaging (capable of visualising atrophic 
changes in the hippocampus and other brain structures). Single photon emission computerised 
tomography (SPECT) and positron emission tomography (PET), are capable of distinguishing between the 
common causes of irreversible dementia24. However, the definitive diagnosis is normally only possible at 
post mortem autopsy. 
Determining the severity of dementia  
For the irreversible forms of dementia, the debilitation caused by the condition is progressive; advancing 
deterioration will affect the patient’s competence in oral hygiene, capacity to consent, and ability to co-
operate with periodontal treatment. Determining the clinical stage and severity of dementia is necessary 
to enable appropriate dental and periodontal treatment planning. There are two commonly used clinical 
staging scales for dementia: the clinical dementia rating (CDR) classification25 and the global deterioration 
scale (GDS)26. The CDR and GDS scales use slightly different terminology. As both are commonly used, 
patients will be best served if their dentists are conversant on both scales which are compared in Table 4.  
The CDR grading can be completed in a relatively quick manner by taking a thorough history from the 
patient and their carer.  The distinction between cognitive impairment and dementia is obscured on the 
CDR scale, this is because making an accurate diagnosis in the early stages of dementia can be a very real 
challenge and for this reason mild cognitive decline (MCI) and mild dementia are grouped as questionable.  
Not everyone who has subjective cognitive impairment (SCI) or MCI will go on to develop dementia. SCI 
has been found to increase the risk of developing dementia by over four-fold over the following 7 years27, 
and MCI has similarly been linked with an increased propensity of developing dementia. The GDS28 is 
preferable for dental treatment planning as it provides more detailed and specific information about the 
patient’s ability to function, which is relevant to periodontal and wider dental treatment planning. 
Importantly the GDS scale also makes a clear distinction between cognitive impairment and mild dementia, 
this is important, because where the dementia is due to one of the conditions listed in Table 2, symptoms 
will deteriorate. Mild dementia often provides a window of co-operation to enable dental treatment to 
lower the chance of dental morbidity as the patient deteriorates into severe dementia. In mild dementia 
most patients will also be able to consent for care themselves and it is the optimal time to begin to include 
carer involvement in dental care.  
 
Medications used to treat dementia and their implications for dental 
management  
Although there is no curative treatment for the forms of dementia listed in Table 2, there are two types of 
drugs prescribed which provide limited symptomatic relief for those with dementia. For a number of 
patients they provide a temporary improvement in cognition, delay deterioration and improve behavioural 
symptoms. They either act on the acetylcholine or glutamate producing neurons.  Early in the AD disease 
process there is a loss of the neurotransmitter acetylcholine due to the dysfunction of cholinergic neurons 
which can affect memory formation. Acetylcholinesterase inhibitors (ACEIs) (donepezil, galantamine and 
rivastigmine) are commonly used as treatments for mild to moderate AD, as they potentiate the effect of 
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acetylcholine, by preventing its breakdown. The N-methyl-D-aspartate (NMDA) antagonist memantine has 
also been approved for use in the management of moderate or severe AD, and for those who cannot 
tolerate acetylcholinesterase inhibitors. Glutamate is an excitatory neurotransmitter which binds to the 
NMDA receptor. Over excitation of this receptor causes an increase in intracellular calcium ions which leads 
to excitotoxicity. The drug memantine binds to the NMDA receptor to inhibit the prolonged influx of 
calcium ions to stop the toxic effect of over-excitation.  The effects of these drugs on cognitive scores tends 
to be small, not everyone is responsive to them and around 30% of people cannot tolerate them due to 
adverse side effects29. Some patients may also take vitamin E supplements as the results of a single study 
have demonstrated reduced rates of cognitive decline for those who took vitamin E compared to placebo, 
yet further research is required to determine whether this finding can be replicated30.  
The side effects of ACEIs that occur in a dose related manner include nausea, vomiting, headaches, 
abdominal pain, and adverse cardiac effects.  While most ACEIs are taken orally, rivastigmine can also be 
administered by transdermal application, which is less likely to cause side-effects. Less commonly, 
galantamine may cause taste-disturbance and rivastigmine is associated with theoretical increased 
salivation31.  There are few interactions of ACEIs and drugs prescribed by dentists, although erythromycin 
and ketoconazole can increase the plasma concentration of galantamine31 to potentiate its side-effects. A 
rare side-effect of the NMDA antagonist, memantine is Stevens-Johnson syndrome, which if occurs, could 
present as blisters affecting the skin and mucous membranes including the oral mucosa and lips. 
In practice ACEIs are commonly associated with reduced salivary flow. Drug induced oral dryness was found 
in 70.5% of those with dementia, yet only 36.5% of controls, and was highly correlated with memantine 
consumption, even after adjustment for potential confounders32.  Hyposalivation is recognised to 
negatively impact on plaque control and increase the likelihood of gingival inflammation33. Due to 
diminished oral hygiene dementia patients are already at greater risk of root caries, as a result of clinical 
attachment loss or gingival recession; this risk is further increased for those who are taking 
anticholinesterases and memantine. 
Antipsychotics (e.g. risperidone, olanzapine and haloperidol), mood stabilizers (e.g. carbamazepine), 
antidepressants and anxiolytics may also be prescribed to control the associated behavioural and 
psychiatric effects of dementia, all of which are similarly associated with reduced levels of saliva.  A possible 
side-effect of long term carbamazepine or haloperidol use is leukopenia34, which could adversely affect the 
host response to periodontal pathogens. Selective serotonin reuptake inhibitors (e.g. sertraline or 
citalopram) tend to be the medications of choice for the treatment of depression in those with dementia 
as tricyclic antidepressants and monoamine oxidase inhibitors can increase confusion. The anti-
hypertensives and proton pump inhibitors used in the management of vascular dementia are also 
associated with reduced salivary flow. Reduced salivary flow as the result of reduced drug clearance rates, 
polypharmacy and inadequate hydration is also recognised among the elderly. Non-nutritious use of food 
to manage behaviours and medications can further increase caries risk35.  
Other side effects of medications used to treat dementia and the polypharmacy common among the 





Importance of carer involvement 
From first diagnosis of dementia it is advisable that a significant other person becomes involved in the 
patient’s dental care, where the patient consents to this. Carers can help patients to feel at ease in the 
dental clinic, which can aid communication, decision making and behavioural management. Their roles will 
increase as the dementia progresses, and include: 
• Provide familiarity in the dental environment particularly for patients who have changed practice 
or dentist.   
• Enable an accurate medical history to be taken.  
• Support the patient, by asking questions relevant to their care, that the patient may not be able 
to articulate themselves and remind the patient of what was said and done during appointments, 
should they have questions once leaving. 
• Provide continuity from appointment to appointment, should the patient forget details of their 
treatment. 
• Assist the patient in remembering their dental appointments. 
• Support the patient in the journey to the dentist. 
• Provide reminders of when to brush and reinforcement of brushing technique on a twice daily 
basis, until such time as the patient deteriorates to the extent that the carer will need to provide 
all oral hygiene for the patient. 
It is essential to communicate how important the carer is to the patient’s dental care. As the patient 
deteriorates, they will have increased need for carer involvement with many of the activities of daily living, 
of which dental care is only one aspect.  This is recognised as a source of stress for carers and loved ones, 
who may be grieving the loss of the person they used to know prior to the onset of dementia.  Given the 
seeming enormity of this situation, dental care can sometimes feel rather insignificant for carers, so it is 
important that they are treated with empathy and valued by the dental team36.  The dental team should 
be aware of the carers’ relationship with the patient and whether they hold lasting power of attorney. 
 
Engendering co-operation for periodontal care 
Those with dementia are less likely to seek dental care. This is likely to be due to a number of reasons 
including practical difficulties in attending appointments, and the perceived attitudes and abilities of the 
dental team in coping with patients who have dementia2 36. It is necessary to dispel patients and carers 
attitudes regarding the limitations of the dental team in coping with the symptoms of dementia by 
providing an environment where patients and carers feel comfortable. As for all patients, it is essential for 
the patient and carer to appreciate why dental treatment is necessary and the benefits of it in reducing 
future dental morbidity. 
Timing of dental appointments are important as the patient may be more agitated or confused at certain 
times of the day, and some days may be worse than others. Appointments should be scheduled at the time 
of day that best suits the patient. Many patients tend to function better in the morning and can become 
increasingly tired and irritable in the afternoon, this can diminish their ability to comply with dental 
treatment.  Co-operation is likely to be variable and not an indication that the patient will permanently be 
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non-compliant. Liaison with carers can elicit whether it will be worth trying again on an alternative day or 
time2. Long appointments are best avoided and, for patients with moderate dementia, are best kept to 
under an hour. Continuity of care is important for those with dementia, this means that for people who 
have been regular dental attenders throughout their lifetime the best environment for treatment is often 
general dental practice. 
Mood swings are commonplace for many patients with dementia; whilst they are a function of dementia 
rather than dental treatment, the dental team need to be aware of approaches to manage them2. When 
conversing with those who have moderate-severe dementia it can be useful to use the VERA framework37 
outlined in Table 5.  The framework provides a structure to ease the patient, interpret communication and 
respond appropriately.  It can be completed in sequence but is more of a tool kit that can be used 
continually during the appointment.  For some, the dental environment will be familiar and comfortable, 
for others it can be daunting and stressful. It is particularly important that dementia patients are helped to 
feel comfortable in dental surroundings as stress will further diminish understanding and co-operation with 
treatment.  
In moderate dementia, the patient is likely to need constant reassurance and repetition of information. As 
dementia severity advances, the dental team will need to respond appropriately to increasingly agitated 
and confused questions and concerns.  If the patient becomes distressed, where the cause of the distress 
is unknown, or cannot be addressed, distraction techniques can be useful. This can be of a conversational 
or practical nature, e.g. oral hygiene demonstration. If the patient becomes confused, repetition of short 
simple instructions can help, especially when delivered in a reassuring tone with a smile, without shouting 
or becoming irritated.  Short and simple phrases are more easily understood, e.g. ‘open your mouth’ is 
better than ‘please let me see inside your mouth’. Where repetition is needed, it is best to repeat the 
phrase or question in the same manner, as rephrasing it is likely to add to the patient’s confusion.  It is the 
quality of communication in the moment that is important for dementia patients, thus behaviours and 
emotions should not be dismissed merely as symptoms of the dementia.  
Many patients with dementia will have a dementia passport, this is a document designed to provide 
information to help professionals involved in the patient’s care. It includes allergies, medications, 
assistance needed, means of relaxation, home and family life, comforters, life history, hobbies and 
interests. Each person with dementia is unique, they will have different interests and react in different 
ways to the same set of circumstances as dictated by their personality and past experiences. For example, 
some patients may feel happy and reassured when listening to music from the 1930’s, others will find that 
depressing. Knowing what the patient likes and dislikes can help put them at ease, should they become 
agitated or more confused during dental treatment. If the patient does not have a dementia passport, a 
simple version can be downloaded and the patient, their carers, friends and family encouraged to complete 
it38. 
Those with dementia are likely to need additional reminders to help them attend dental appointments.  It 
is best to find out which form of reminder will be best for the patient and use that format. If the patient is 
not used to using a mobile phone or computer, text messages and emails will be useless. For others who 
use electronic calendars they may be the most useful form of memory aid.  With the patients consent it 





Oral health and dementia care pathways have been published by the National Institute of Care Excellence, 
integration of the two pathways remains a future aspiration39-41. There are two crucial points in the 
dementia patients care pathway when an oral health assessment is advisable. The first is shortly after the 
diagnosis and the second is shortly after entering a care home2. The aim of these assessments is to gather 
enough information to enable appropriate treatment planning to reduce the risk of future dental 
morbidity. In severe dementia, pain and infection of dental origin can adversely affect patients’ behaviour 
and quality of life, this is likely to be compounded by the fact that the patient will most likely be unable to 
recognise and communicate their symptoms or co-operate with dental treatment, potentially necessitating 
future crisis management. 
A complete assessment of oral soft and hard tissues is essential to diagnose all forms of dental disease 
including caries, failed restorations, unrestorable teeth and teeth with a high likelihood of endodontic 
infection. The durability of fixed and removable prostheses and health of peri-implant tissues will also be 
assessed.  The Basic Periodontal Examination (BPE)42 should be used to screen for periodontal disease in 
all patients with dementia.  The periodontal assessment should be completed in the same manner as for 
all patients in accordance with British Society of Periodontology guidelines42 43, yet for those patients with 
moderate and severe dementia, this may not be possible in a single appointment due to the patient’s 
limited ability to co-operate.  For patients with periodontal pockets >4mm radiographic images that show 
circumferential bone levels and periapical tissues will be required for each tooth affected.  For the patient 
who requires an image of each tooth, an orthopantomograph (OPT) may be preferable to full mouth 
periapical radiographs, as when the patient can remain still for the longer exposure time, this requires less 
compliance than multiple periapical radiographs. 
As there is a high incidence of xerostomia amongst those with dementia, it is worth assessing intraoral 
dryness using the Challacombe Oral Dryness Scale44. This information can be used to tailor the risk of the 
patient suffering further dental disease, such as root caries and candidiasis.  
When in the severe stages of dementia, the patient will be unlikely to recognise and vocalise dental pain.  
For those who have severe dementia, if there is no other recognisable cause, a sudden deterioration of 
behaviour may indicate the patient is experiencing oral pain2. As there can be other causes of altered 
behaviour, all relevant information should be gathered from the patient’s regular care team. The signs that 
are often indicative of dental pain are listed in Table 6. Where the patient is suffering from dental pain 
sedation may be required to enable oral assessment, as this is complicated by consent and co-morbidity 
issues it is beyond the scope of general practice and discussed to a greater extent in part 2 of this series. 
 
Conclusion 
Dental assessment is an important aspect of the holistic health care for those with dementia. As many 
people are living with undiagnosed dementia, recognising dementia is crucial in dental practice, because 
of the associated implications for dental and periodontal care. Furthermore, the medications commonly 
used to manage dementia patients have numerous oral effects. Knowledge and understanding of the 
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patient’s cognitive condition can aid communication and help engender support for the dental care of 
vulnerable dementia patients who often have unmet dental needs.  
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Table 1. Conditions responsible for causing reversible (treatable) dementia1,2  
D Drugs [e.g. Korsakoff’s syndrome due to excessive alcohol especially when associated 
with poor diet and thiamine deficiency] 
E Emotions [e.g. depression, anxiety] 
M Metabolic [e.g. pernicious anaemia] 
E Endocrine [e.g. hypo & hyperthyroidism] 
N Nutritional deficiency [e.g. folic acid, thiamine, vitamin B12] 
T Tumours & trauma of the brain [e.g. concussion, contusion, subdural haematoma] 
I Infections [e.g. tuberculosis, syphilis, human immunodeficiency virus] 
A Arteriosclerosis of cerebral vessels [e.g. transient ischaemic attack] 




Table 2. Conditions responsible for causing irreversible (degenerative) dementia2,3  
P Parkinson’s disease 
H Huntington’s disease 
A Alzheimer’s disease. It can be in the familial early onset form or more commonly the 
sporadic late onset form.  
N Neural infection with prions [e.g. Creutzfeld Jacob Disease], viruses [e.g. AIDS] or 
bacteria [e.g. tertiary syphilis, especially when combined with HIV] 
T Traumatic vascular damage, vascular disease and stroke 
O Other cerebral cellular damage [e.g. Lewy body disease, Fronto-temporal dementia 
and Pick’s disease, Intra-cerebral pressure] 
M Malignancy [e.g. brain tumours] 





Table 3. Signs & Symptoms of Dementia 
Domain Signs & symptoms 
Memory Loss Inability to recall recent events e.g. previous appointments, holidays, important news. 
Normally memory loss is noticed by someone else. 




Lack of orientation in time and place. 
Unable to spell a common 5 letter word backwards. 
Reduced ability to focus on things that are of interest. 
Language 
impairment 
Anomia or inability to find the correct word. 
Impaired understanding. Speech and writing difficult to understand. 
Inability to repeat a sentence or word. 
Visuospatial 
impairment 
Inability to copy complex shapes 
Difficulty identifying faces that are well known to the patient. 
Forgetting how to get back home.  Hallucinations. 
Apraxia Inability to execute motor responses despite intact motor functions. 
Difficulty performing lifelong hobby. 
Impaired executive 
function 
Impaired judgement & difficulty making decisions. 
Difficulty managing finances. 
Forgetting steps when preparing a meal or using a household appliance. 
Putting things in unusual places e.g. toothbrush in the fridge. 
Altered behaviour 
& social interaction 
Disinhibition, mood swings, aggression, suspicious, fearful. 
Lack of motivation for activities that were previously enjoyed. 
Uncharacteristically passive or irritable. Paranoia possible. 
Depression, anxiety, long periods in front of the television. 
Altered sensory 
perception 




Table 4. Comparison of terminology used to grade the clinical severity of dementia26-28  
 GDS stage & terminology CDR stage & terminology 
Normal adult 1: Normal Cognitive Decline 0: No cognitive impairment 
2: Subjective Cognitive 
Decline 
 3: Mild Cognitive Decline 0.5: Questionable cognitive 
impairment Dementia 4: Mild dementia 
5: Moderate dementia 1: Mild dementia 
6: Moderately severe 
dementia 
2: Moderate dementia 
3: Severe dementia 





Table 5. VERA framework to aid communication with people who have dementia37  
V Validate the person 
Acknowledge that the person is trying to communicate. Avoid criticising and include 
the patient in all conversations with carers and third parties 
E Emotional context 
Try to appreciate this even when communication is unclear e.g. ‘You sound 
frustrated’ 
Validate the person’s feelings  
R Reassurance 
Use verbal and non-verbal communication 
A Activity 
To discover more about the persons concerns and address their unmet needs  
 
 
Table 6. Behavioural changes in the patient with severe dementia which may be indicative of oral pain2 
R Restlessness, aggression and refusal to co-operate 
E Exacerbated drooling 
S Sleep disturbances 
P Pulling at the face 
E Eating habits altered and refusal to eat 
C Communication changes, with increased moaning and shouting 
T Tolerance of dentures diminished for those who previously wore well-fitting dentures 
Mnemonic formulated using information in cited source 
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